This site contains promotional content intended for UK Healthcare Professionals and other relevant decision makers | Not a HCP? Visit our Public Site.
Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below.
EYLEA® (aflibercept) 8 mg
EYLEA 114.3 mg/mL is indicated for the treatment of patients with neovascular (wet) age-related macular degeneration (nAMD) and visual impairment due to diabetic macular oedema (DMO).
GAIN CONFIDENCE IN FLUID CONTROL
In the PULSAR and PHOTON trials, EYLEA® (aflibercept) 8 mg provided lasting non-inferior vision gains with fewer injections vs EYLEA 2 mg in nAMD and DMO. Click for more about our clinical trial data in nAMD or DMO.
Now, clinical trial and real-world evidence has shown EYLEA 8 mg can provide sustained fluid resolution whilst minimising treatment burden vs EYLEA 2 mg.
In clinical trials, EYLEA 8 mg showed:
Image reference:
Image references:
Image references:
*Primary endpoint in PULSAR and PHOTON. BCVA gains from baseline with EYLEA 8 mg were non-inferior to EYLEA 2 mg at Week 48 in both trials. Vision gains were maintained through Week 96 for EYLEA 8 mg and EYLEA 2 mg in both trials.
Recent UK audit data has shown that these RCT results are now being replicated, with the drying effect of EYLEA 8 mg observed from the first injection.
Click on the tabs below to hear what the experts have to say; see how EYLEA 8 mg has benefitted patients like yours and explore real-world audit data below.
Medical retina lead at Bristol Eye Hospital, Serena Salvatore, reveals her own experience of the drying effects of EYLEA 8 mg.
Prescribing information for EYLEA® (aflibercept) can be found here.
Listen to this episode of the Macular Minute podcast where a panel of three consultant ophthalmologists talk about their experience with the drying effects of EYLEA 8 mg.
Prescribing information for EYLEA® (aflibercept) 8 mg can be found here.
Prescribing information for EYLEA® (aflibercept) 2 mg can be found here.
Please refer to the links below to hear from other experts who have used EYLEA 8 mg, and explore a variety of on-demand resources created in collaboration with both local and internationally recognised leaders in medical retina.
Abbreviations
2Q8, 2 mg every 8 weeks. BCVA, best-corrected visual acuity. CRT, central retinal thickness. DMO, diabetic macular oedema. nAMD, neovascular age-related macular degeneration. RCT, randomised controlled trial.
PP-EYL-GB-2837 | May 2025
- Referencesexpand_less
- 1EYLEA® 114.3 mg/mL Summary of Product Characteristics.
- 2Korobelnik J-F. Intravitreal aflibercept 8 mg injection in patients with neovascular age-related macular degeneration: 48-week results from the Phase 3 PULSAR trial. Retina Society. 2–5 November 2022. Pasadena, USA. Oral presentation.
- 3Lanzetta P, et al. Intravitreal aflibercept 8 mg injection in patients with neovascular age-related macular degeneration: 60-week and 96-week results from the Phase 3 PULSAR trial. EURETINA. 5–8 October 2023. Amsterdam, The Netherlands. Oral presentation.
- 4Do D. Aflibercept 8 mg for diabetic macular edema: 48-week results from the Phase 2/3 PHOTON trial. ARVO. 23–27 April 2023. Palo Alto, USA. Oral presentation.
- 5Patel P, et al. A 96-week PULSAR Phase 3 trial post-hoc analysis: rapid and sustained fluid control with aflibercept 8 mg every 12 weeks or longer, as defined by fluid-free status at Weeks 16, 48 and 96 stratified by baseline CRT and BCVA. EURETINA. 19–22 September 2024. Barcelona, Spain. Oral presentation.
- 6Wykoff CC. Aflibercept 8 mg for diabetic macular edema: 96-week results from the Phase 2/3 PHOTON trial. EURETINA. 5–8 October 2023. Amsterdam, The Netherlands. Oral presentation.
- 7Bayer. Data on file. EYL032.